Clinical trials: in China
Allergic Rhinitis
Efficacy and Safety of Xinyi Powder in Patients With Allergic Rhinitis and the Lung Deficiency and Cold Syndrome
By observing the improvement of Xinyi Powder powder and simulated agent on the symptoms, symptom and sign scores, nasal symptom VAS scores, and quality of life of patients with allergic rhinitis due to lung deficiency and cold…
- Trial name
- NCT07899515
- Testing
- Xinyi Powder
- Where
- 2 sites in China
- Volunteers
- 228 people
- Sponsor
- Nanjing University of Traditional Chinese Medicine
Puberty Changes
Indicators and Evaluation of Efficacy of Yin-nourishing and Fire-reducing Chinese Medicine for Girls With Rapid Progression of Early Puberty
1. Evaluate whether AMH and SHBG have differential expression before and after the diagnosis of rapid and slow progression types of early puberty and whether this difference has a predictive effect on the rapid progression type.
- Trial name
- NCT06820931
- Testing
- Xuandi Ziyin Mixture
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Children's Hospital of Fudan University
CABG, Graft Failure
Pilot Trial of Colchicine for Graft Failure in CABG
This is a single-center, prospective, randomized, open-label, assessor-blinded, blank-controlled exploratory (pilot) trial evaluating the feasibility of oral colchicine after coronary artery bypass grafting (CABG).
- Conditions
- CABG, Graft Failure, Colchicine
- Trial name
- CoCAB-Pilot (NCT06802926)
- Testing
- Colchicine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Dravet Syndrome
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS.
- Trial name
- NCT06660394
- Testing
- LP352
- Where
- 105 sites in United States, Australia and 16 more
- Volunteers
- 108 people
- Sponsor
- Longboard Pharmaceuticals
Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Stellate Ganglion Block, Prolonged Disorders of Consciousness
Stellate Ganglion Block on Postoperative Sleep Status in Patients With Prolonged Disorders of Consciousness
This is a prospective, single-centre, single-arm, self-controlled, exploratory pilot study. The goal of this clinical trial is to learn about the effect of preoperative administration of stellate ganglion block on postoperative…
- Conditions
- Stellate Ganglion Block, Prolonged Disorders of Consciousness, Sleep
- Trial name
- NCT07274683
- Testing
- stellate ganglion block with 0.5% ropivacaine
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Beijing Tiantan Hospital
Ventricular Thrombus
Effectiveness and Safety of Different Antithrombotic Therapy for the Treatment of Ventricular Thrombus
To observe the effectiveness and safety of different therapies-non-vitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) or antiplatelet agents and non-antithrombotic therapy - for the treatment of VT.
- Trial name
- NCT05006677
- Testing
- non-vitamin K antagonist oral anticoagulants (NOACs), vitamin K antagonists (VKAs), antiplatelet agents
- Where
- China
- Volunteers
- 196 people
- Sponsor
- China National Center for Cardiovascular Diseases
Fibrosing Interstitial Lung Disease
A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD)
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary…
- Trial name
- NCT07366034
- Testing
- Nerandomilast
- Where
- 47 sites in United States, Argentina and 20 more
- Volunteers
- 35 people
- Sponsor
- Boehringer Ingelheim
Chronic Inflammatory Demyelinating Polyneuropathy, CIDP
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
The main purpose of this study is to demonstrate the efficacy and safety of empasiprubart in adults with CIDP. The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6…
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Trial name
- emnergize (NCT07091630)
- Testing
- Empasiprubart IV
- Where
- 89 sites in United States, Argentina and 23 more
- Volunteers
- 160 people
- Sponsor
- argenx
Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Acute Coronary Syndromes
AI-Assisted Coronary Syndrome Subtyping From Admission History of Present Illness: A Clinician Reader Study
This study will evaluate whether an OCR-LLM-based clinical decision support framework improves clinicians' accuracy in classifying coronary syndrome subtypes from admission history of present illness.
- Conditions
- Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)), Acute Coronary Syndromes, ST-segment Elevation Myocardial Infarction (STEMI), Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)
- Trial name
- OCR-LLM-CHD (NCT07449429)
- Testing
- OCR-Prompt-LLM Information Extraction and Classification Workflow (OCR-Prompt-LLM), Manual Clinical Data Review
- Where
- China
- Volunteers
- 10 people
- Sponsor
- China National Center for Cardiovascular Diseases
Polyneuropathy, Inflammatory Demyelinating, Chronic
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating…
- Trial name
- LTS (NCT06859099)
- Testing
- Riliprubart Prefilled Pen (PFP)
- Where
- 63 sites in United States, Argentina and 22 more
- Volunteers
- 300 people
- Sponsor
- Sanofi
Infant Allergy, Infant Gut Health
Study on the Impact of Different Feeding Methods on Allergy Prevention and Digestive Absorption in Infants and Young Children
Based on a real-world research paradigm, this study aims to evaluate the performance of infants fed via different methods-specifically goat milk formula, control formula, and breastfeeding-regarding allergy prevention and protein…
- Conditions
- Infant Allergy, Infant Gut Health, Infant Respiratory Diseases, Infant Feeding Scale
- Trial name
- NCT07886437
- Testing
- Observation, biological sample collection: stool
- Where
- China
- Volunteers
- 696 people, healthy volunteers welcome
- Sponsor
- Tsinghua University
Hemophilia
A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
This is a parallel, Phase 3, two-arm, open-label study to evaluate the efficacy and safety of treatment with fitusiran prophylaxis administered to male pediatric participants (aged 1 to <12 years) who have severe hemophilia A or…
- Trial name
- ATLAS-KIDS (NCT07285460)
- Testing
- Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
- Where
- 37 sites in United States, Belgium and 10 more
- Volunteers
- 85 people
- Sponsor
- Sanofi
Myopia
VEP for Assessment SMILE Visual Quality
To evaluate the subjective and objective postoperative visual quality employing pattern visual evoked potential (P-VEP) following small incision lenticule extraction (SMILE).
- Trial name
- SMILE VEP (NCT07889752)
- Testing
- small incision lenticule extraction (SMILE)
- Where
- China
- Volunteers
- 84 people
- Sponsor
- yuhao shao
Neovascular Age-related Macular Degeneration (nAMD)
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients…
- Trial name
- CONSTANCE (NCT06795048)
- Testing
- Faricimab
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 274 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer, NSCLC
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line…
- Trial name
- NCT06422143
- Testing
- Pembrolizumab, sac-TMT, Carboplatin
- Where
- 217 sites in United States, Argentina and 24 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Adolescent Idiopathic Scoliosis (AIS)
Protocol for a Randomized Controlled Trial of a Clinician-Supervised Home-School-Hospital-Linked Digital Health Platform-Supported Conservative Management Pathway for AIS
Adolescent idiopathic scoliosis (AIS) brings substantial physical and psychological burden to affected teenagers, and current conservative follow-up management is fragmented under routine clinical settings.
- Trial name
- NCT06314594
- Testing
- Routine Guideline-Based Conservative Care, Clinician-Supervised, Platform-Assisted Conservative Management
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Hangzhou Medical College
Carcinoma, Non-Small-Cell Lung
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with…
- Trial name
- NCT06875310
- Testing
- Adagrasib, Pembrolizumab, Carboplatin
- Where
- 317 sites in United States, Argentina and 33 more
- Volunteers
- 630 people
- Sponsor
- Mirati Therapeutics Inc.
Obsessive-Compulsive Disorder (OCD), Transcranial Magnetic Stimulation
Continuous Theta-Burst Stimulation for Obsessive-Compulsive Disorder: An Open-Label Study
This single-arm, open-label study evaluates short-term symptom improvement and tolerability of continuous theta-burst stimulation (cTBS), a non-invasive brain stimulation technique, in adults with obsessive-compulsive disorder…
- Conditions
- Obsessive-Compulsive Disorder (OCD), Transcranial Magnetic Stimulation, Electroencephalography
- Trial name
- NCT07896837
- Testing
- Continuous Theta-Burst Stimulation
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Anhui Medical University
Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a suitable dose of a combination study treatment, obrixtamig and ZL-1310.
- Conditions
- Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
- Trial name
- NCT07707895
- Testing
- Obrixtamig, ZL-1310, Atezolizumab
- Where
- 27 sites in United States, Australia and 9 more
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.